Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials

Abstract Background While quadruplet induction therapies deepen responses in newly diagnosed multiple myeloma patients, their impact on peripheral blood stem cell (PBSC) collection remains incompletely understood. This analysis aims to evaluate the effects of prolonged lenalidomide induction and isa...

Descripció completa

Dades bibliogràfiques

Autors principals:	Joseph Kauer, Emma P. Freundt, Anita Schmitt, Niels Weinhold, Elias K. Mai, Carsten Müller-Tidow, Hartmut Goldschmidt, Marc S. Raab, Katharina Kriegsmann, Sandra Sauer
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2023-11-01
Col·lecció:	BMC Cancer
Matèries:	Multiple myeloma Stem cell mobilization Lenalidomide Elotuzumab Isatuximab
Accés en línia:	https://doi.org/10.1186/s12885-023-11507-9
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!